OpGen, Inc. (OPGN)

NASDAQ: OPGN · IEX Real-Time Price · USD
3.026
-0.004 (-0.13%)
At close: Jul 19, 2024, 3:59 PM
2.940
-0.086 (-2.84%)
After-hours: Jul 19, 2024, 5:41 PM EDT
-0.13%
Market Cap 4.08M
Revenue (ttm) 2.67M
Net Income (ttm) -26.66M
Shares Out 1.35M
EPS (ttm) -31.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,755
Open 2.958
Previous Close 3.030
Day's Range 2.900 - 3.026
52-Week Range 1.650 - 38.400
Beta -0.65
Analysts Hold
Price Target n/a
Earnings Date Jul 8, 2024

About OPGN

OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. OpGen, Inc. was incorporated in 2001 and is headquartered in Rockville, Maryland. [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date May 5, 2015
Employees 100
Stock Exchange NASDAQ
Ticker Symbol OPGN
Full Company Profile

Financial Performance

In 2023, OpGen's revenue was $3.42 million, an increase of 31.11% compared to the previous year's $2.61 million. Losses were -$32.67 million, -12.38% less than in 2022.

Financial Statements

News

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating t...

2 months ago - GlobeNewsWire

OpGen Announced 1-for-10 Reverse Stock Split

ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split ...

2 months ago - GlobeNewsWire

OpGen Provides Update on Business Operations and Strategic Opportunities

ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and ...

2 months ago - GlobeNewsWire

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating...

3 months ago - GlobeNewsWire

OpGen Announces Acquisition of Preferred Stock by David Lazar

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Laz...

4 months ago - GlobeNewsWire

OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

8 months ago - GlobeNewsWire

OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to h...

10 months ago - GlobeNewsWire

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

1 year ago - GlobeNewsWire

OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

ROCKVILLE, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infecti...

1 year ago - GlobeNewsWire

OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement

ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

1 year ago - GlobeNewsWire

OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 20...

1 year ago - GlobeNewsWire

OpGen's Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND

ROCKVILLE, Md., July 19, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

1 year ago - GlobeNewsWire

OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe

ROCKVILLE, Md., June 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infecti...

1 year ago - GlobeNewsWire

OpGen's Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments

ROCKVILLE, Md., June 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

1 year ago - GlobeNewsWire

OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference

ROCKVILLE, Md., June 20, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

1 year ago - GlobeNewsWire

OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to ...

1 year ago - GlobeNewsWire

OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2023...

1 year ago - GlobeNewsWire

OpGen Announces Closing of $3.5 Million Public Offering

ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to ...

1 year ago - GlobeNewsWire

OpGen Announces Pricing of $3.5 Million Public Offering

ROCKVILLE, Md., May 01, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to ...

1 year ago - GlobeNewsWire

OpGen's Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND

ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

1 year ago - GlobeNewsWire

OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare

ROCKVILLE, Md., April 18, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

1 year ago - GlobeNewsWire

OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel

ROCKVILLE, Md., April 18, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

1 year ago - GlobeNewsWire

OpGen's Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND

ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

1 year ago - GlobeNewsWire

OpGen's Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics

ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

1 year ago - GlobeNewsWire

CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) -- In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the financial tables were incorrect. The corrected relea...

1 year ago - GlobeNewsWire